In an unsurprising case of “duh!” federal investigators from the Government Accountability Office (GAO) came to the conclusion that the FDA is not doing well at one of its main responsibilities. The FDA is failing to properly track drugs after they hit the market. The GAO, Congress’ nonpartisan investigative department, discovered problems.
According to the GAO report, “FDA’s data on post-market safety issues and studies were found to be incomplete, outdated, to contain inaccuracies, and to be stored in a manner that made routine, systematic analysis difficult.”
[…]
The president of the nonprofit consumer research group, the National Center for Health Research, Diana Zuckerman said, “We are shortcutting an important part of the approval process in the hope that we get the information later, but now we’re finding out that’s not happening.”
Dr. Zuckerman is absolutely correct and the GAO report proves it.
To read the full article, click here.